NASDAQ:IBB iShares Biotechnology ETF (IBB) Price, Holdings, & News $167.50 +3.23 (+1.97%) As of 06/3/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsSEC FilingsShort InterestTrendsBuy This Stock About iShares Biotechnology ETF (NASDAQ:IBB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IBB alerts:Sign Up Key Stats Today's Range$163.37▼$167.6250-Day Range$160.41▼$176.6652-Week Range$123.61▼$179.64Volume1.02 million shsAverage Volume1.45 million shsMarket Capitalization$7.87 billionAssets Under Management$7.56 billionDividend Yield0.23%Net Expense Ratio0.45%Aggregate RatingModerate Buy ETF Overview iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc. Read More iShares Biotechnology ETF ExpensesTypeIBBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.45%0.56%0.57%0.54%0.53%Other Expenses0.00%0.47%0.55%0.52%0.55%Total Expense0.45%0.74%0.76%0.73%0.73%Fee Waiver0.00%-0.71%-0.64%-0.50%-0.62%Net Expense0.45%0.59%0.63%0.62%0.60% Receive IBB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IBB ETF News HeadlinesAV Laboratories, Founded by Pioneers of IVF Solutions, to Launch Fertility Clinic Program Featuring Its Award-Winning Skincare at ESHRE 2026 in LondonMay 21, 2026 | businesswire.comBiotech Investors Are Tuning Out the MAHA ChaosMay 20, 2026 | wsj.comSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. But at a $1.75 trillion valuation and 266 times earnings, early institutional holders may be looking for someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure behind Colossus - still trading at a fraction of its potential value. No IPO allocation required.June 4 at 1:00 AM | Behind the Markets (Ad)2 Ways to Play the Big Pharma Patent Cliff (IBB)With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.May 14, 2026 | marketbeat.comEqual-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position NowApril 23, 2026 | 247wallst.comXBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026April 7, 2026 | 247wallst.comSee More Headlines IBB ETF - Frequently Asked Questions How have IBB shares performed this year? iShares Biotechnology ETF's stock was trading at $168.77 at the start of the year. Since then, IBB shares have decreased by 0.8% and is now trading at $167.50. When did iShares Biotechnology ETF's stock split? Shares of iShares Biotechnology ETF split before market open on Friday, December 1st 2017.The 3-1 split was announced on Tuesday, November 7th 2017. The newly minted shares were payable to shareholders after the market closes on Thursday, November 30th 2017. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Who are iShares Biotechnology ETF's major shareholders? Top institutional shareholders of iShares Biotechnology ETF include Bank of America Corp DE (15.28%), Royal Bank of Canada (1.57%), Janney Montgomery Scott LLC (1.33%) and PNC Financial Services Group Inc. (0.67%). How do I buy shares of iShares Biotechnology ETF? Shares of IBB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iShares Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that iShares Biotechnology ETF investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Fund Details IssueriShares Fund NameiShares Biotechnology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:IBB Inception Date2/5/2001 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkNYSE Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings255 Fund Statistics Assets Under Management$7.56 billion Average Daily Volume$1.47 million Discount/Premium0.10% Administrator, Advisor and Custodian AdministratorJ.P. Morgan Chase Bank, N.A. AdvisorBlackRock Fund Advisors CustodianJPMorgan Chase Bank, N.A. DistributorBlackRock Investments, LLC Transfer AgentJ.P. Morgan Chase Bank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableOptionable Options Volume202 Put Options83 Call Options119 Short Interest13,010,000 shs Miscellaneous Outstanding Shares47,000,000Beta0.72 Creation Unit50,000 Creation Fee$614.00 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Top 10 IBB HoldingsGilead Sciences (NASDAQ:GILD)Holding Weight: 7.52%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 7.37%Amgen (NASDAQ:AMGN)Holding Weight: 7.25%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 5.93%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 3.61%argenex (NASDAQ:ARGX)Holding Weight: 3.49%Biogen (NASDAQ:BIIB)Holding Weight: 2.68%Natera (NASDAQ:NTRA)Holding Weight: 2.48%Revolution Medicines (NASDAQ:RVMD)Holding Weight: 2.44%United Therapeutics (NASDAQ:UTHR)Holding Weight: 2.24%Full Holdings DetailsIBB Sector ExposureIBB Industry Exposure This page (NASDAQ:IBB) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...Traders Agency | SponsoredThe SpaceX S-1 changes everythingSpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...Crypto 101 Media | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Biotechnology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
